Navigation Links
Insmed Completes Sale of Follow-On Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
Date:3/31/2009

RICHMOND, Va., March 31 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, announced today that it has successfully closed the sale of all of the Company's assets related to its follow-on biologics business to a subsidiary of Merck & Co., Inc. As a result of this closing, Insmed has now received $130 million, the aggregate purchase price, for the assets. After fees, taxes and other costs related to the transaction, net proceeds are expected to be approximately $123 million.

As a result of the transaction, Merck purchased all rights to Insmed's follow-on biologic assets, including INS-19 and INS-20, as well as control of the Boulder, Colorado-based manufacturing facility. Merck, through an affiliate, has assumed the facility's lease and ownership of all the equipment in the building. In addition, Merck has offered positions to employees of the Boulder facility. Insmed has retained its Richmond, VA corporate office, which houses its Clinical, Regulatory, Finance, and Administrative functions, in support of the continuing IPLEX(TM) program.

Insmed will continue to carefully evaluate potential uses of the proceeds from the transaction.

RBC Capital Markets served as exclusive financial advisor to Insmed on the transaction and the review of strategic alternatives, and provided a fairness opinion to the Company's Board of Directors. McGuire Woods, LLP acted as legal advisor to Insmed and Fried, Frank, Harris, Shriver & Jacobson LLP acted as legal advisor to Merck.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein development experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to develop IPLEX(TM) may be unsuccessful our common stock could be delisted from the Nasdaq Capital Market and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

    Investor Relations Contact:
    Brian Ritchie - FD
    212-850-5683
    brian.ritchie@fd.com

    Media Contact:
    Irma Gomez-Dib - FD
    212-850-5761
    irma.gomez-dib@fd.com


'/>"/>
SOURCE Insmed Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Insmed Announces FDA Issues Statement Regarding Position on Allowing Patients With ALS Access to IPLEX(TM) Under an IND
2. Insmed and Premacure Announce European Orphan Designation for IPLEX(TM) in Retinopathy of Prematurity in Infants
3. Insmed Gains Royalty-Free Worldwide Rights for IPLEX(TM) in Connection with Potential Expanded Access ALS Programs
4. Insmed to Present at Upcoming Healthcare Conferences
5. Insmed to Present at the IBC 5th Annual Global Follow-On Biologics Conference
6. Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM)
7. Immunotech Completes Merger Acquisition
8. Arcadia Completes New Financing; Previews Fourth Quarter Results
9. Roche Completes Acquisition of Genentech
10. Phyhealth Completes Funding Transaction with AccessKey IP, Inc.
11. Endo Pharmaceuticals Completes Acquisition of Indevus Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. ... of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related to Death ... podcasted thereafter . Dr. Bernie Siegel, author of a plethora of essential ...
(Date:4/29/2016)... Southlake, Texas (PRWEB) , ... April 29, 2016 , ... ... and neck pain, is proud to announce one of their physicians has been invited ... Osteopathic Family Physicians (Texas ACOFP) Family Practice Review conference on April 30, 2016. ...
(Date:4/29/2016)... ... ... Melanoma is the deadliest type of skin cancer. Although only about 1 percent of skin ... More than 10,000 people are expected to die of melanoma this year. The risk increases ... of the most commonly diagnosed cancers in young women. A recent breakthrough in genetic studies ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, ... round of funding led by Eastside Partners, with participation from existing investor Martin ... customer base and accelerate its technology and product roadmap. , “Jvion ...
(Date:4/29/2016)... ... ... Nike Softball Camp at the College of Brockport in New York is ... 10-18. All facets of the game will be covered; hitting, fielding, base-running, and team ... the finest softball facilities in the region. The outstanding professional college staff complement and ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... , le 27 Avril 2016 ... a progressé de +5% sur le trimestre, soutenu ... de consommables  Croissance de +16% des ... Mauna Kea Technologies (Euronext : MKEA, FR0010609263 ; ... confocale laser, annonce aujourd,hui son chiffre d,affaires pour ...
(Date:4/27/2016)... April 27, 2016 Elekta today ... platform will be the focal point of seven scientific ... European Society for Radiotherapy & Oncology, taking place April ... a state-of-the-art radiotherapy system and a high-field MRI scanner ... see the patient,s anatomy in real time. The MR-linac ...
(Date:4/27/2016)... , April 27, 2016   Zillion ... digital health technology platform, which specializes in live ... into scalable digital products, Zillion enables companies to ... empower consumers to take control of their health. ... video conferencing – including one-to-one, group and webcast ...
Breaking Medicine Technology: